Why Pfizer's 2017 Was Mediocre at Best Post author:Sam Post published:December 12, 2017 Post category:BioPharma Pfizer’s 2017 wasn’t horrible. Just ho-hum. Source: BioSpace You Might Also Like 3 Cases of Brain Damage Force the FDA to Slap a Hold on Bellicum's Lead Drug January 30, 2018 Turns Out Editas Medicine's R&D Deal With Allergan Could be Worth $1 Billion March 22, 2017 Agile Therapeutics, Inc. Reports Fourth Quarter And Full Year 2016 Financial Results March 8, 2017
